MMGH works solely with public sector customers, health agencies, NGOs and foundations active in global public health including:

  • Bill & Melinda Gates Foundation
  • Christian Medical College, Vellore
  • European Commission
  • Gavi, the Vaccine Alliance
  • Global Task Force on Cholera Control
  • INCLEN Trust
  • Measles & Rubella Initiative
  • South-Eastern European Health Network
  • United Nations Foundation
  • University of York
  • World Health Organisation (Headquarters, Regional and Country Offices)

Since its creation MMGH has worked on more than 50 projects spanning the spectrum of product and program lifecycles. Below are some significant examples. 


Preparation of the typhoid vaccine policy recommendations through the WHO SAGE Working Group

MMGH supported the WHO Initiative for Vaccine Research in facilitating a SAGE Working Group review of the scientific evidence and programmatic considerations supporting use of typhoid vaccines with a focus on typhoid conjugate vaccines. The typhoid vaccine recommendations were discussed and endorsed by the WHO SAGE in October 2017 and subsequently published as a WHO Position Paper.

Preparation of the guidance document to support countries introducing health worker influenza vaccination

MMGH supported the WHO Initiative for Vaccine Research in reviewing the scientific evidence on HW influenza vaccination, collating currently available immunization strategies, and synthesising a practical introduction manual to support countries introducing HW influenza vaccination.


Preparation of an investment case for the new cholera elimination strategy

MMGH supported the Global Task Force on Cholera Control in assessing and defining the financial needs and benefits of the new strategy “Ending Cholera: A Global Roadmap to 2030” and translating those into a comprehensive investment case to be used by donors and countries. The project scope includes a wide range of multisectoral interventions across WASH, immunization, disease surveillance and case management. MMGH worked collaboratively across multiple sectors and ensured effective project management. Subsequent to the completion of the project, MMGH was also engaged for the definition of a forecasting and monitoring framework as well as for the design of processes and tools to support the management of the initiative.

Development of the 2020-2030 strategic framework for the Measles & Rubella Initiative

MMGH is currently supporting the Measles & Rubella Initiative (M&RI) leadership and management teams in the definition of the structure of the post-2020 partnership and framework, including the vision, guiding principles, and objectives. MMGH partnered with members of the M&RI agencies to review finding of a situational analysis and a broad stakeholders consultation performed as part of the project, supported the input of M&RI to the new WHO “Immunization Agenda 2030”, supported the initiative’s teams in identifying the key strategic axes and long-term goals of the new strategy, the mechanisms which will lead to the necessary change and the implications for and linkages with other immunization and broader health strategies.

Definition of the Middle-Income Country strategy for European Region

MMGH supported the WHO Regional Office for Europe to develop a strategic framework to address the challenges faced by the middle-income countries in the region. The strategic framework served as the basis for the subsequent development of a detailed roadmap to implement the recommended actions to address the identified challenges. MMGH partnered with the regional office in defining a situational analysis, facilitated internal brainstorming and meetings, assessed risk and opportunities and supported the identification of the main strategic axis coherently with the Regional Vaccine Action Plan.

Definition of the strategic guidance for the Accelerated Control of Japanese Encephalitis in the Western Pacific Region

MMGH supported the WHO Regional Office for Western Pacific in developing a guide for accelerating control of Japanese encephalitis in the region that suggests regional targets, defines regional strategies and activities to accomplish the targets and provides a framework for countries to develop national plans tailored to their situations. MMGH collaborated with the WHO Regional Office, country representatives and global experts in Japanese encephalitis to facilitate a meeting of experts, draft the guidance and work towards an endorsed and funded strategy for Japanese encephalitis control in the region.

Situational analysis for maternal immunization and antenatal care service delivery

MMGH supported the WHO Initiative for Vaccine Research and Maternal, Newborn Child and Adolescent Health department in conducting a Bill & Melinda Gates Foundation-sponsored project that investigates and analyses the status of maternal immunization delivery strategies in low and middle-income countries. This includes developing a typology to classify health systems in terms of how they deliver vaccines to pregnant women and exploring approaches to improve country readiness for delivering new maternal vaccines such as future respiratory syncytial virus and group B streptococcal vaccines.


Evaluation of enteric fever surveillance pilot program

MMGH supported the WHO Initiative for Vaccine Research in assessing the feasibility and reliability of integrating surveillance of enteric fever (EF) and invasive non-typhoidal salmonellosis (iNTS) in the WHO-coordinated Global Invasive Bacterial Vaccine Preventable Disease Surveillance Network. In Ghana, MMGH conducted two successive evaluations of the EF and iNTS surveillance pilot programme using a newly developed structured assessment tool. The evaluation included on-site reviews of clinical and epidemiological aspects of the surveillance system, the assessment of the participating microbiology laboratories and blood culture areas and of site-specific and overall data quality and management.

Evaluations in tier 2 surveillance sites for the National Surveillance System for Enteric Fever in India (NSSEFI).

MMGH conducted an independent external evaluation of the tier 2 sites of the NSSEFI. The tier 2 sites are secondary level hospitals, conducting surveillance on hospitalized patients with suspected enteric fever. Most of the hospitals are located in remote areas in India and some of them have established blood culture capacity as part of the project. The evaluation which was conducted after the completion of one full year of surveillance helped in identifying problems with case detection and enrolment, laboratory investigation and data management and to take corrective measures to address them.


MMGH presents the outcome of the OCV WG assessment – Lagos, September 2017


Preparation of Gavi vaccine applications and Comprehensive Multi-Year Plan (cMYP) development in Lao PDR

MMGH supported the Ministry of Health and the WHO Country Office of Lao PDR in developing successful GAVI applications for the introduction of HPV and Rotavirus vaccines. MMGH co-led a thorough review of the National Immunization Program (NIP). On the basis of this NIP review MMGH assisted the Ministry of Health with establishing and updating a cMYP for the Lao PDR NIP for 2019-2023. This plan specifically lays out the detailed implementation and monitoring of existing and new vaccines and provides detailed insights into the financial needs and shifts in resource allocations in view of the country’s upcoming transition from donor support.

Preparation of Gavi application for HPV vaccine introduction in Cambodia

MMGH assisted the National Immunization Program (NIP), Ministry of Health Cambodia, and the WHO Country Office in Phnom Penh with the Gavi application process for the introduction of HPV vaccine. MMGH conducted a review of earlier pilot program implementation and derived lessons learned, facilitated the decision-making of the country Technical Working Group for Health on defining target age groups and delivery settings, and assisted in establishing detailed implementation plans including coverage monitoring, cold chain expansion, communications and demand creation. MMGH supported the NIP in responding to additional queries throughout the Gavi approval process as well as in developing robust vaccine demand forecasts and financial budgets in view of the country’s imminent transition from Gavi support. The application was approved by the Gavi Independent Review Committee (IRC) in March 2019.

Development of a framework to support the establishment of Programme Performance Monitoring Unit in Myanmar

MMGH assisted the Gavi Secretariat and Ministry of Health of Myanmar in the development of a roadmap for the establishment of a Programme Performance Monitoring Unit (“PPMU”), including its staffing, logistics, and related cost estimates. MMGH conducted a gap analysis aimed at identifying key challenges; defined, in coordination with the Ministry of Health, principles and long term objectives of the PPMU; developed design options (e.g., potential governance and accountability structures, high level mapping of key partners and requirements for functionality of PPMU); and developed a roadmap to implement recommendations, including validation from all key stakeholders.


Evaluation of the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE)

MMGH supported the WHO Department of Immunization, Vaccines and Biologicals and the Expert Advisory Group on SAGE Evaluation (EAGSE) in assessing the relevance, effectiveness and quality of SAGE’S work and deliverables, to assure that it continues to provide high quality strategic advice in all areas of the evolving immunization and global health agenda. This included scoping the evaluation, performing stakeholder consultations, gathering and analysing findings , facilitating their review by the EAGSE, developing recommendations and preparing the evaluation report .

The final report of the evaluation can be consulted here

Mid-Term review of the Regional Strategic Plan for Immunization for the African Region

MMGH supported to the WHO Regional Office for Africa (AFRO) in performing the mid-term review of the Regional Strategic Plan for Immunization 2014-2020. MMGH prepared an extensive desk review, facilitated a face-to-face session of the external review panel at AFRO HQ, summarized and consolidated review findings, assisted in the development of recommendations and in the presentation of a final evaluation report to the AFRO Regional Immunization Technical Advisory Group.

The final report of the evaluation can be consulted here


MMGH facilitates the Mid-term review of the AFRO Regional Strategic Plan on Immunisation – Brazzaville, October 2017

Evaluation of the WHO’s Global Vaccine Action Plan 2011-2020

MMGH is currently supporting the WHO Department of Immunization, Vaccines and Biologicals and the Decade of Vaccine (DOV) working group of SAGE in the overall evaluation of strengths and weaknesses of the current plan, its monitoring and evaluation and accountability framework and the added value it provided to the global immunization arena. The project also included the definition of a comparative landscape analysis of the global immunization arena in 2010 and 2018 and a description of the overall progress between 2010 and 2018 on the goals and strategic objectives. In this project, MMGH partnered with the Task Force for Global Health.

The final report of the evaluation can be consulted here

Mid-term Evaluation of the European Vaccine Action Plan (EVAP)

MMGH supported to the WHO Regional Office for Europe (EURO) in performing the mid-term review of the EVAP 2015-2020. MMGH supported WHO EURO in collating and analysing available information to measure progress against the EVAP goals and strategic objectives and summarize the findings into a report for the review of a Working Group of the European Technical Advisory Group of Experts and in preparing a report for presentation to the WHO Regional Committee for Europe.

The final report of the evaluation can be consulted here

Review of Gavi-supported data strengthening activities 

MMGH supported the Monitoring & Evaluation unit of the Secretariat of Gavi, the Vaccine Alliance, in performing a review and synthesis of Gavi-funded data strengthening partner activities (WHO, UNICEF, US CDC, WB) and presented findings at a Monitoring, Data Systems and Strategic Information partner workshop which defined the future direction of this work. 


Preparation of the business case for a Schistosomiasis vaccine

MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a vaccine for Schistosomiasis. MMGH coordinated a group of experts in developing vaccine use cases and preferred product characteristics, worked with modelers from the Imperial College London and the University of Warwick to assess the epidemiological and economic impact, assessed the regulatory, product development and vaccine delivery strategy, and assembled the public health value proposition. 

Definition of a product development strategy for a Leishmaniasis vaccine

MMGH created a product development plan to guide the University of York in further development and implementation of a candidate leishmaniasis vaccine. The plan incorporates development of a target product profile, an evaluation of the chemistry, manufacturing and controls, clinical development and regulatory strategies. The plan further recognizes the financial constraints and need to maximize the public health impact of the vaccine for a neglected tropical disease. The University of York is expected to use the plan to both seek partnerships with potential manufacturing, development and commercial partners as well as to secure funding for the subsequent development phases.

Preparation of the business case for a Macrofilaricide drug for the treatment of Onchocerciasis

MMGH is currently supporting the Bill & Melinda Gates Foundation in assessing the public health and financial viability of macrofilaricide drug for the treatment of Onchocerciasis. MMGH led development of potential drug use cases and refined the relevant aspects of a target product profile, worked with modelers from the Imperial College London and the Erasmus Medical Center to assess the epidemiological and economic impact of a macrofilaricide and assembled a full public health and financial value proposition.

Definition of an advocacy strategy for a new vaccine against invasive non-typhoidal Salmonella (iNTS)

MMGH is part of the Vacc-iNTS consortium, made up of 12 partners from 8 different countries including 3 invasive non-typhoidal salmonella (iNTS) disease- endemic countries, an initiative aimed to advance the development of an iNTS vaccine by conducting a Phase I clinical study in adults of Europe and Africa. The project, funded by the European Union’s Horizon 2020 Research and Innovation Programme, will investigate the immunogenicity and safety of the iNTS-GMMA vaccine, a novel vaccine based on outer membrane blebs released by genetically modified bacteria, developed by the GSK Vaccine Institute for Global Health (GVGH). As part of this effort MMGH will focus on strengthening a collaborative network to enhance disease awareness and drive advocacy.


Market Information for Access to Vaccine (MI4A) Initiative

MMGH provides ongoing support to the WHO Expanded Program on Immunization (EPI) in partnership with Linksbridge SPC for the piloting and establishment of an initiative aimed at enhancing countries’ access to safe, effective, quality, and affordable vaccines. MMGH manages the consultation with manufacturers, the definition of the methodological aspects of the project, the assessment of current and future supply and the identification of bottlenecks on the supply-demand balance and of potential mitigating measures. As per August 2019 the project has covered vaccines bacillus Calmette-Guarin, Diphtheria and Tetanus-containing, Human Papilloma virus, Meningococcal Meningitis vaccines. Analyses of Measles-containing and Pneumococcal vaccines are currently underway.

MI4A logo

More information can be found at: Market Information for Access to Vaccines

Improving access to affordable vaccine supply in Member States of the South-Eastern Europe Health Network (SEEHN)

MMGH supported the Vaccine-Preventable diseases and Immunization unit of WHO Europe in further operationalising the vision and principles set in the SEEHN’s Ministers of Health Podgorica Declaration which focus on securing access to sufficient and affordable vaccine supply. In support to WHO, MMGH developed and co-led an initial workshop among representative from the Member States designed to increase participant awareness of opportunities to improve access to affordable vaccine supply and to identify potential opportunities for in-country and cross-country cooperation. MMGH advised specifically on developing the agenda, developing and presenting meeting content, facilitating sessions and providing meeting reports including recommendations for next steps.

© MMGH Consulting GmbH, last update: October 2019